Mayron Antonio Candia-Puma

This paper identifies T. cruzi-specific B-cell epitopes using computational methods and experimental validation, achieving high diagnostic accuracy for Chagas disease.

This paper identifies VCX2 as a potential biomarker and therapeutic target in HCC, and identifies Luteolin-5-O-glucoside as a lead compound from Peruvian natural products through computational analysis.

This study evaluates Malvidin and Echioidinin as antileishmanial agents through in vitro and in silico analyses, finding Malvidin more potent and less toxic than Echioidinin and Amphotericin B.

This study reviews and analyzes preclinical treatments for Chagas disease using animal models, finding promising candidates but limited clinical success.

The paper evaluates natural products for anti-leishmanial activity against Leishmania infantum MOGS using CADD, identifying Ocotillone and Subsessiline as promising candidates with pH-dependent inhibition and favorable ADMET profiles.

PeruNPDB is a database of 280 Peruvian natural products designed for in silico drug screening, highlighting the importance of biodiversity in drug discovery.

This study identifies Malvidin as a potential drug candidate for leishmaniasis by screening natural product analogs using in silico methods targeting the parasite's arginase enzyme.